ClinicaliQ Trial Snapshot
- Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis — Recruiting • Non-phase study • Neurology • NCT07111637.
- What is being tested: AI-assisted MRI technology designed to improve the speed, accuracy, and consistency of brain and spinal cord imaging interpretation for MS patients across NHS services, with the goal of enabling earlier diagnosis and treatment decisions.
- Patient eligibility overview: The trial involves MS patients requiring brain and/or spinal cord MRI scans for diagnosis or monitoring purposes, representing the full spectrum of NHS MS care from suspected cases to established disease requiring treatment assessment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Multiple Sclerosis (MS) is a long-term disease that affects over 150,000 people in the UK. Starting treatment early is important for managing Multiple Sclerosis (MS). It is also essential to monitor the treatment to see if it is working and to switch treatments if needed. Magnetic resonance imaging (MRI) is the only accepted tool to monitor how well the treatment is working. Current evaluation of brain Magnetic resonance imaging (MRI) scans requires visual inspection, of which sensitivity is degraded by human, and technical factors, such as lack of time, fatigue…
Eligibility Snapshot
- : * Clinically Isolated Syndrome suggestive of demyelination (CIS) or definitive diagnosis of MS. * Undergoing MRI head investigation. * On an MS DMT pathway. * Access to a smartphone, tablet or computer.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.